Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Deals & Financings

VC fundings, mergers and acquisitions, and other financing events...

Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets

Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio

Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal

Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal

Coherus Returns Rights for Avastin Biosimilar to Innovent

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022